600 participants
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-05-29
- Start Date:
- 2024-05-24
- Completion:
- 2029-02-19
Conditions
- Non-small Cell Lung Cancer
Interventions
- DRUG
- OTHER
- BIOLOGICAL
No Results Yet